Innovative ETFs ChannelDrug Pricing Reforms Keep Pressure on Biotech, Healthcare ETFsBy Max ChenSeptember 26, 2019
Innovative ETFs ChannelBiotech ETFs Strengthen After Judge Blocks Trump’s Drug Pricing RuleBy Max ChenJuly 9, 2019
Innovative ETFs ChannelAbbVie, Allergan Deal Puts Spotlight on Pharmaceutical ETFsBy Max ChenJune 25, 2019
Innovative ETFs ChannelBiotech ETFs Are Breaking Out on Pfizer’s Array Biopharma DealBy Max ChenJune 17, 2019
Innovative ETFs ChannelHealthcare, Biotech ETFs Plunge on Mounting Political PressuresBy Max ChenApril 18, 2019
Equity ETF ChannelA Targeted ETF to Capture M&A, Consolidation in the Biotech SpaceBy Max ChenApril 10, 2019
Innovative ETFs ChannelHealthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain OutlookBy Max ChenMarch 6, 2019
Innovative ETFs ChannelA Specialty Biotech ETF Strengthens on Optimism Over CRISPR AdvancementsBy Max ChenMarch 1, 2019
Innovative ETFs ChannelPharmaceutical ETFs Break Out on Horizon Pharma’s Positive Drug ResultsBy Max ChenFebruary 28, 2019
Equity ETF ChannelSpark Therapeutics Acquisition Sparks Rally in Biotechnology ETFsBy Max ChenFebruary 25, 2019
Innovative ETFs ChannelSpecialized Biotech ETF Rallies on MacroGenics Positive Trial ResultsBy Max ChenFebruary 6, 2019
Core ETF ChannelHealthcare ETFs Slip After Abbot Lab’s Revenue Miss, Weak OutlookBy Max ChenJanuary 23, 2019
